Attached files
| file | filename |
|---|---|
| EX-10.1 - CONSULTING AGREEMENT AMENDMENT - Pharma-Bio Serv, Inc. | pbsv_ex101.htm |
UNITED
STATES
SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
FORM
8-K
CURRENT REPORT
PURSUANT
TO SECTION 13 or
15(d) OF THE
SECURITIES EXCHANGE
ACT OF 1934
Date of report
(Date of earliest event reported): January 17,
2017
Pharma-Bio Serv,
Inc.
(Exact Name of
Registrant as Specified in Its Charter)
Delaware
(State or Other
Jurisdiction of Incorporation)
|
0-50956
|
20-0653570
|
|
(Commission File
Number)
|
(I.R.S. Employer
Identification No.)
|
|
6 Road 696, Dorado,
Puerto Rico
|
00646
|
|
(Address of
Principal Executive Offices)
|
(Zip
Code)
|
|
(787)
278-2709
|
|
(Registrant’s
Telephone Number, Including Area Code)
|
|
|
|
(Former Name or
Former Address, if Changed Since Last Report)
|
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐ Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item
5.02. Departure of Directors or
Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain
Officers.
On January 17,
2017, Pharma-Bio Serv, Inc. (the “Company”) amended the
Consulting Agreement, dated January 1, 2014, as amended, by and
among the Company, Strategic Consultants International, LLC and
Elizabeth Plaza (the “Consulting Agreement”), effective
January 1, 2017 (the “Amendment”). The
Amendment extends the term of the Consulting Agreement for an
additional year to December 31, 2017 (the “Extension
Term”). The Company will compensate consultant a
monthly retainer of $42,000 during the Extension
Term. All other terms and conditions of the Consulting
Agreement remain the same.
A copy of the
Amendment is attached as Exhibit 10.1 to this report and
incorporated herein by reference.
Item
9.01. Financial Statements and
Exhibits.
(d) Exhibits
|
Exhibit
No.
|
|
Description
|
|
|
|
|
|
|
Consulting
Agreement Amendment, dated January 17, 2017, by and among
Pharma-Bio Serv, Inc., Strategic Consultants International, LLC and
Elizabeth Plaza, effective January 1, 2017.
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
PHARMA-BIO
SERV, INC.
|
|
|
|
|
|
|
|
|
Date: January 19,
2017
|
By:
|
/s/ Pedro J.
Lasanta
|
|
|
|
|
Pedro J.
Lasanta
|
|
|
|
|
Chief Financial
Officer, Vice President Finance
|
|
|
|
|
and Administration
and Secretary
|
|
EXHIBIT
INDEX
|
Exhibit
No.
|
|
Description
|
|
|
|
|
|
|
Consulting
Agreement Amendment, dated January 17, 2017, by and among
Pharma-Bio Serv, Inc., Strategic Consultants International, LLC and
Elizabeth Plaza, effective January 1, 2017.
|